Albireo Pharma (ALBO) Stock Forecast, Price & News

Albireo Pharma (NASDAQ:ALBO) Frequently Asked Questions

Is Albireo Pharma a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Albireo Pharma stock.
View analyst ratings for Albireo Pharma or view top-rated stocks.

When is Albireo Pharma's next earnings date?

Albireo Pharma is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022.
View our earnings forecast for Albireo Pharma.

How were Albireo Pharma's earnings last quarter?

Albireo Pharma, Inc. (NASDAQ:ALBO) issued its quarterly earnings results on Monday, May, 16th. The biopharmaceutical company reported ($2.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.02) by $0.17. Albireo Pharma had a negative trailing twelve-month return on equity of 73.93% and a negative net margin of 72.02%. During the same period last year, the firm posted ($2.29) EPS.
View Albireo Pharma's earnings history.

What price target have analysts set for ALBO?

3 brokerages have issued 12-month price targets for Albireo Pharma's shares. Their forecasts range from $66.00 to $80.00. On average, they anticipate Albireo Pharma's stock price to reach $72.67 in the next twelve months. This suggests a possible upside of 251.0% from the stock's current price.
View analysts' price targets for Albireo Pharma or view top-rated stocks among Wall Street analysts.

Who are Albireo Pharma's key executives?

Albireo Pharma's management team includes the following people:

• Mr. Ronald H. W. Cooper, CEO, Pres & Director (Age 59, Pay $1.1M)
• Mr. Simon Nicolas Reade Harford, CFO & Treasurer (Age 61, Pay $687.78k)
• Ms. Martha J. Carter, Chief Regulatory Officer (Age 70, Pay $710.69k)
• Dr. Per-Goran Gillberg, Co-Founder & VP of Devel.
• Dr. Jan P. Mattsson Ph.D., Chief Scientific Officer, MD (Sweden) & Co-Founder (Age 58)
• Ms. Joan Connolly, Chief Technology Officer
• Mr. Jason G. Duncan, Chief Legal Officer, Gen. Counsel & Sec. (Age 48) (LinkedIn Profile)
• Ms. Michelle Graham, Chief HR Officer (Age 55)
• Dr. Kristina Torfgard, VP & Global Project Head
• Ms. Pamela Stephenson M.P.H., Chief Commercial Officer (Age 54) (LinkedIn Profile)

Who are some of Albireo Pharma's key competitors?

Some companies that are related to Albireo Pharma include Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), Travere Therapeutics (TVTX), Supernus Pharmaceuticals (SUPN), Xenon Pharmaceuticals (XENE), Arcus Biosciences (RCUS), Taro Pharmaceutical Industries (TARO), Xencor (XNCR), Sierra Oncology (SRRA), Prothena (PRTA), BELLUS Health (BLUSF), Cryoport (CYRX), IVERIC bio (ISEE), 23andMe (ME) and Celularity (CELU).
View all of ALBO's competitors.

What other stocks do shareholders of Albireo Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

What is Albireo Pharma's stock symbol?

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Who are Albireo Pharma's major shareholders?

Albireo Pharma's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.94%), Chicago Capital LLC (5.23%), Vanguard Group Inc. (5.05%), State Street Corp (4.69%), Decheng Capital Management III Cayman LLC (2.68%) and Prosight Management LP (2.48%). Company insiders that own Albireo Pharma stock include Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Ronald Harold Wilfred Cooper and Simon NR Harford.
View institutional ownership trends for Albireo Pharma.

Which major investors are selling Albireo Pharma stock?

ALBO stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., State Street Corp, Platinum Investment Management Ltd., Citigroup Inc., Prosight Management LP, Privium Fund Management B.V., BlackRock Inc., and Blair William & Co. IL. Company insiders that have sold Albireo Pharma company stock in the last year include Jason Duncan, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Ronald Harold Wilfred Cooper, and Simon NR Harford.
View insider buying and selling activity for Albireo Pharma or view top insider-selling stocks.

Which major investors are buying Albireo Pharma stock?

ALBO stock was acquired by a variety of institutional investors in the last quarter, including Decheng Capital Management III Cayman LLC, Nicholas Investment Partners LP, Chicago Capital LLC, Prudential Financial Inc., MAI Capital Management, Endurant Capital Management LP, Vanguard Group Inc., and Dimensional Fund Advisors LP.
View insider buying and selling activity for Albireo Pharma or or view top insider-buying stocks.

How do I buy shares of Albireo Pharma?

Shares of ALBO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Albireo Pharma's stock price today?

One share of ALBO stock can currently be purchased for approximately $20.70.

How much money does Albireo Pharma make?

Albireo Pharma has a market capitalization of $400.79 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34.03 million in net income (profit) each year or ($1.76) on an earnings per share basis.

How many employees does Albireo Pharma have?

Albireo Pharma employs 130 workers across the globe.

When was Albireo Pharma founded?

Albireo Pharma was founded in 2003.

What is Albireo Pharma's official website?

The official website for Albireo Pharma is www.albireopharma.com.

How can I contact Albireo Pharma?

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at [email protected], or via fax at 203-796-5001.